Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Infectious Diseases
Volume 2015 (2015), Article ID 498608, 4 pages
Case Report

Mycobacterium sherrisii Lung Infection in a Brazilian Patient with Silicosis and a History of Pulmonary Tuberculosis

1Clinics Hospital, Federal University of Goiás, 1a Avenida, s/n, Setor Leste Universitário, 74605-020 Goiânia, GO, Brazil
2Department of Tropical Medicine and Dermatology, Tropical Pathology and Public Health Institute, Federal University of Goiás, Goiânia, GO, Brazil
3Hospital of Tropical Diseases Dr. Anuar Auad, Goiânia, GO, Brazil

Received 29 June 2015; Accepted 30 September 2015

Academic Editor: Larry M. Bush

Copyright © 2015 Carolina de Oliveira Abrão and João Alves de Araújo Filho. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Nontuberculous mycobacteria (NTM) diseases became relevant with the emergence and spread of HIV and are also related to lung infection in non-HIV individuals with structural lung diseases. Mycobacterium sherrisii is a NTM first characterized in 2004. Only a few cases have been reported. The aim of this case report is to describe the first detailed case of infection with M. sherrisii in a patient with silicosis and history of pulmonary tuberculosis. A 50-year-old HIV-negative white male, previous smoker, with silicosis and a history of treated pulmonary tuberculosis developed a worsening of cough and expectoration pattern, and two sputum samples were positive for acid-fast bacilli. Presumptive treatment for pulmonary tuberculosis was initiated with rifampin, isoniazid, pyrazinamide, and ethambutol, but, at month 5 of treatment, despite correct medication intake and slight improvement of symptoms, sputum bacilloscopy remained positive. Sputum cultures were positive Mycobacterium sherrisii. Treatment regimen was altered to streptomycin (for 2 months), ethambutol, clarithromycin, rifabutin, and trimethoprim-sulfamethoxazole. M. sherrisii should be considered a possible etiological agent of lung infections in patients with pneumoconiosis and history of tuberculosis.